# flask-webapp

해당 부분은 Python과 spotify api를 활용한 가벼운 ML이 포함된 웹 앱 구축 프로젝트입니다.\
ML은 음악 스타일의 이진 분류를 위한 RandomForestClassifier를 채택했습니다.\
웹 앱 구축을 위하여 Flask, SQLite 등을 사용했습니다.

spotify api를 통하여 이진 분류를 위한 Upbeat, Chillout 플레이리스트 내 음악 리스트와,\
나의 최근 들은 음악의 데이터를 가져왔습니다.

Python Files\
__init__ : Flask를 run하는 python 파일입니다. db를 쿼리를 통해 호출하고, html과 함께 시각화합니다. \
__RFClassifier__ : 랜덤포레스트 이진분류로 pickle 모델을 생성하는 부분입니다. 미리 선별하여 만들어진 플레이리스트 내 음악들이 있는 sample.json을 활용합니다.\
__recent_music__ : 최근 들었던 음악을 가져와 db에 저장하는 함수입니다. 해당 과정에서 RFClassifier를 통하여 만들어진 pickle모델을 통해 분류 예측값이 함께 저장됩니다.\
__practice__ : 연습장입니다.

현재 db 재구성과 개선점 추가를 진행 중에 있습니다.

<div class="wd_body wd_news_body" wd_print_url="https://galmedpharma.investorroom.com/2023-06-01-Galmed-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Developments?printable=1" wd_resize="formatNews">
<p><span class="legendSpanClass"><span class="xn-location">TEL AVIV, Israel</span></span>, <span class="legendSpanClass"><span class="xn-chron">June 1, 2023</span></span> /<a href="http://www.prnewswire.com/" target="_blank">PRNewswire</a>/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended <span class="xn-chron">March 31, 2023</span> and recent developments</p>
<div dir="ltr" id="prni_dvprnejpgece6left" style="width: 100%; text-align: left;"><img align="middle" alt="Galmed Pharmaceuticals Logo" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1713483%2FGalmed_Pharmaceuticals_Logo.jpg" id="prnejpgece6left" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" title="Galmed Pharmaceuticals Logo"/></div><p><b>Recent Developments</b></p><div wd_move_after=".wd_body &gt; p ~ p|.wd_body &gt; p">
<div class="wd_asset_modal wd_asset_modal_main" style="display:none;">
<div class="wd_slideshow wd_asset_slideshow_wrapper wd_asset_slideshow_main_wrapper" tabindex="-1" wd_resize="resizeSlideshow"><div class="wd_slideshow-cropper"><ul class="wd_layout-slideshow wd_asset_slideshow_list wd_asset_slideshow_main_list wd_slideshow-list"><li class="wd_asset_slideshow wd_asset_type_3 wd_asset_3-97 wd_slideshow-item wd_slideshow-current" wd_ajax_url="https://galmedpharma.investorroom.com/press-releases?gallery=97&amp;ajax=ajax&amp;op=modal" wd_item_hash="assets_3:97">
<div class="wd_gallery-modal">
<style type="text/css">

.wd_gallery-modal {
	height: 100%;
	width: 100%;
}
.wd_gallery_modal {
	height: 100%;
	width: 100%;
}
.wd_gallery_modal .wd_info {
	overflow: auto;
}
.wd_gallery_modal .wd_image {
	height: 75%; /* will be overridden when load complete */
	width: 100%;
}
.wd_gallery_modal .wd_image img {
	height: 100%;
}
.wd_resizing .wd_image img {
	height: auto;
	max-width: 100%;
	max-height: 100%;
}
</style>
<div class="wd_gallery_modal" wd_resize="distributeHeight">
<div class="wd_image" wd_fix_height="1" wd_proportion="2">
<img border="0" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?w=2700" title="Galmed_Pharmaceuticals_Logo"/>
</div>
<div class="wd_info" wd_max_height="200">
<div class="wd_title">Galmed_Pharmaceuticals_Logo</div>
<div class="wd_summary"><p>Galmed Pharmaceuticals Logo</p></div>
<div class="wd_hi_res_link_wrapper">Download: <a class="wd_hi_res_link" href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=publish" target="">Hi Res</a></div>
</div>
</div>
</div>
<script type="text/javascript">
				if (webDriver && webDriver.loadScripts)
					webDriver.loadScripts([{"type":"script_url","url":"js\/jquery-webdriver.js","id":"jquery-webdriver.js"},{"type":"script_url","url":"js\/webdriver.js","id":"webdriver.js"},{"type":"script_url","url":"js\/wd_resize.js","id":"wd_resize.js"},{"type":"script_url","url":"js\/wd_distribute_height.js","id":"wd_distribute_height.js"}]);
			</script>
</li></ul></div><a class="wd_slideshow-arrow wd_slideshow-prev fa fa-chevron-left" href="#prev" style="display: none;" title="Previous"><span class="wd_sr-only">Previous Item</span></a><a class="wd_slideshow-arrow wd_slideshow-next fa fa-chevron-right" href="#next" style="display: none;" title="Next"><span class="wd_sr-only">Next Item</span></a></div>
</div>
<div class="wd_asset_carousel_aspect" style="height: 100px;" wd_fixed_aspect="height:32:9:100:200" wd_resize="adjustAspectRatio">
<div class="wd_carousel wd_asset_wrapper wd_asset_carousel_wrapper wd_asset_carousel_main_wrapper" wd_resize="resizeCarousel"><div class="wd_carousel-cropper"><ul class="wd_layout-carousel wd_asset_list wd_asset_carousel_list wd_asset_carousel_main_list wd_carousel-list" style="position: absolute; top: 0px; left: 52.5px;" wd_carousel_options='{"class":"wd_asset_wrapper wd_asset_carousel_wrapper wd_asset_carousel_main_wrapper"}' wd_onload="loadCarousel"><li class="wd_asset_carousel wd_asset_type_3 wd_asset_3-97 wd_carousel-item wd_carousel-current" style="height: 100%;">
<div class="wd_gallery_asset">
<div class="wd_asset_image">
<img border="0" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?w=600" title="Galmed_Pharmaceuticals_Logo"/>
</div>
<div class="wd_icon_overlay">
<a class="wd_link_underlay" href="https://galmedpharma.investorroom.com/2023-06-01-Galmed-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Developments#assets_3:97" tabindex="-1"></a>
<div>
<div class="wd_icon_container"><a href="https://galmedpharma.investorroom.com/2023-06-01-Galmed-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Developments#assets_3:97"><span class="fa fa-search-plus"></span><span class="wd_sr-only wd_sr-only-focusable">View File</span></a> <a href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=publish" target=""><span class="fa fa-download"></span><span class="wd_sr-only wd_sr-only-focusable">Download File</span></a></div>
</div>
</div>
<div class="wd_title_overlay">
		Galmed_Pharmaceuticals_Logo
	</div>
</div>
</li></ul></div><a class="wd_carousel-arrow wd_carousel-prev fa fa-chevron-left" href="#prev" style="display: none;"></a><a class="wd_carousel-arrow wd_carousel-next fa fa-chevron-right" href="#next" style="display: none;"></a></div>
</div>
</div>
<ul type="disc"><li>Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;</li><li>Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health <span class="xn-org">Virginia Commonwealth University</span>;</li><li>Formed a strategic partnership with Onkai, Inc., leading an investment round of <span class="xn-money">$6 million</span> in Onkai, an AI-powered digital platform that facilitates health equity in underserved communities across the US, Enabling faster and diverse enrollment to clinical trials;</li><li>The Company is discontinuing its evaluation of strategic alternatives; and</li><li>Nasdaq notified the Company that it regained compliance with the Nasdaq minimum bid price rule.</li></ul><p><b>Financial Summary – First Quarter 2023 vs. First Quarter 2022:</b></p>
<ul type="disc"><li>Cash and cash equivalents, short term deposit, restricted cash and marketable debt securities totaled <span class="xn-money">$12.2 million</span> as of <span class="xn-chron">March 31, 2023</span>, compared to <span class="xn-money">$13.8 million</span> at <span class="xn-chron">December 31, 2022</span>.</li><li>Net loss amounted to <span class="xn-money">$1.8 million</span>, or <span class="xn-money">$1.09</span> per share, for the three months ended <span class="xn-chron">March 31, 2023</span>, compared to a net loss of <span class="xn-money">$6.1 million</span>, or <span class="xn-money">$3.67</span> per share, for the three months ended <span class="xn-chron">March 31, 2022</span>.</li><li>Research and development expenses amounted to approximately <span class="xn-money">$1.1 million</span> for the three months ended <span class="xn-chron">March 31, 2023</span>, compared to approximately <span class="xn-money">$4.8 million</span> for the three months ended <span class="xn-chron">March 31, 2022</span>. The decrease resulted primarily from a decrease in clinical trial expenses.</li><li>General and administrative expenses amounted to approximately <span class="xn-money">$0.9 million</span> for the three months ended <span class="xn-chron">March 31, 2023</span>, compared to approximately <span class="xn-money">$1.3 million</span> for the three months ended <span class="xn-chron">March 31, 2022</span>. The decrease resulted primarily from a decrease in share based compensation and professional services expenses.</li><li>Financial income, net amounted to approximately <span class="xn-money">$0.2 million</span> for the three months ended <span class="xn-chron">March 31, 2023</span>, compared to financial expense of <span class="xn-money">$0.05 million</span> for the three months ended <span class="xn-chron">March 31, 2022</span>.</li></ul><p><b><i>About Galmed Pharmaceuticals Ltd.</i></b></p>
<p>We are a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. We have focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. We are also collaborating with the <span class="xn-org">Hebrew University</span> in the development of Amilo-5MER, a 5 amino acid synthetic peptide.</p>
<p><b><i>Forward-Looking Statements:</i></b></p>
<p>This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's planned PSC clinical trial and our pivotal Phase 3 ARMOR trial, or the ARMOR Study (if re-initated) or any other pre-clinical or clinical trials; completion and receiving favorable results of our planned PSC clinical trial and our the ARMOR Study for Aramchol (if re-initiated) or any other pre-clinical or clinical trial; the impact of the COVID-19 pandemic; regulatory action with respect to Aramchol or any other product candidate by the FDA or the EMA; the commercial launch and future sales of Aramchol or any other future products or product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramchol or any other product candidate in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramchol or any other product candidate; Galmed's expectations regarding the commercial market for NASH patients or any other indication; third-party payor reimbursement for Aramchol or any other product candidate; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; the development and approval of the use of Aramchol or any other product candidate for additional indications or in combination therapy; and Galmed's expectations regarding licensing, acquisitions and strategic operations/. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on <span class="xn-chron">March 29, 2023</span>, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<p> </p>
<p> </p>
<div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tbody><tr><td class="prngen2" colspan="9" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>GALMED PHARMACEUTICALS LTD.</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen2" colspan="9" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Consolidated Balance Sheets</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="9" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>U.S. Dollars in thousands, except share data and per share data</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>As of</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>As of</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>March 31,</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>December 31,</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2023</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2022</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen7" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Unaudited</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen7" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Audited</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Assets</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Current assets</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Cash and cash equivalents</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,672</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,016</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Short term deposit</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">754</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Restricted Cash</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">114</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">114</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Marketable debt securities</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">9,726</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">11,769</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other receivables</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">568</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">825</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total current assets</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">12,834</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">14,724</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Right of use assets</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">176</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">223</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Property and equipment, net</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">105</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">114</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Investment in convertible loan</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,676</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,500</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total non-current assets</b></span></p>
</td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,957</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,837</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total assets</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">14,791</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">16,561</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Liabilities and stockholders' equity</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Current liabilities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Trade payables</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,266</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,560</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other payables</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">535</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">534</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total current liabilities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,801</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">3,094</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Non-current liabilities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Lease obligation</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">44</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total non-current liabilities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">44</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Ordinary shares par value NIS 0.01 per share; Authorized 20,000,000; Issued and</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">outstanding: 1,680,232 shares as of March 31, 2023 and December 31, 2022 *)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">70</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">70</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Additional paid-in capital</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">200,435</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">200,138</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Accumulated other comprehensive loss</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(645)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(745)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Accumulated deficit</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(187,870)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(186,040)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total stockholders' equity</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">11,990</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">13,423</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total liabilities and stockholders' equity</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen11" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">14,791</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen11" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">16,561</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="2"><p class="prnml4"><span class="prnews_span">The accompanying notes are an integral part of the interim consolidated financial statements.</span></p>
<p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span">*) Retroactively adjusted to reflect the reverse split</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="9" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr></tbody></table></div><p> </p>
<p> </p>
<div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tbody><tr><td class="prngen4" colspan="10" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>GALMED PHARMACEUTICALS LTD.</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen2" colspan="10" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Consolidated Statements of Operations (Unaudited)</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="10" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>U.S. Dollars in thousands, except share data and per share data</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="4" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="5" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>Three months ended</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen7" colspan="5" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>March 31,</b></span></p>
</td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="3" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>2023</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="3" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>2022</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Research and development expenses</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,083</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">4,796</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">General and administrative expenses</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">919</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,296</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Total operating expenses</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,002</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">6,092</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Financial (income) expense, net</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prnpr2 prnpl2 prnvab prntar prnsbtb1 prnrbrb1 prnbbbs prnsblb1" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(172)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">51</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Net loss</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,830</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">6,143</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Basic and diluted net loss per share</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1.09</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen6" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">3.67</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="2"><p class="prnml4"><span class="prnews_span">Weighted-average number of shares outstanding used in<br/>computing basic and diluted net loss *)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">  per share</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,680,232</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="1" rowspan="1"><br/></td><td class="prngen11" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,672,566</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="9" rowspan="1"><p class="prnml4"><span class="prnews_span">*) Retroactively adjusted to reflect the reverse split</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr></tbody></table></div><p> </p>
<p> </p>
<div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tbody><tr><td class="prngen4" colspan="8" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>GALMED PHARMACEUTICALS LTD.</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen2" colspan="8" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Consolidated Statements of Cash Flows (Unaudited)</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="8" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>U.S. Dollars in thousands</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="4" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen5" colspan="6" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>Three months ended</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen7" colspan="6" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>March 31,</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen13" colspan="3" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>2023</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen13" colspan="2" rowspan="1"><p class="prnml4"> </p>
<p class="prnml4"><span class="prnews_span"><b>2022</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Cash flow from operating activities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Net loss</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(1,830)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen10" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">(6,143)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Adjustments required to reconcile net loss to net cash used in operating activities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Depreciation and amortization</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">8</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Stock-based compensation expense</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">297</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">457</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Amortization of premium on marketable debt securities</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">10</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">31</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Amortization of discount on long term assets</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(176)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Interest income from short-term deposits</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(4)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Loss from realization of marketable debt securities</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">32</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">145</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Finance expenses</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">4</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">(10)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Changes in operating assets and liabilities:</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Decrease in other accounts receivable</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">257</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">282</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Decrease in trade payables</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(294)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">(36)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Increase (decrease) in other accounts payable</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">(187)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Net cash used in operating activities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen14" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(1,695)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="1" rowspan="1"><br/></td><td class="prngen14" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">(5,452)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Cash flow from investing activities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Purchase of available for sale securities</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,494</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Investment in short term deposits</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(750)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">-</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Consideration from sale of available for sale securities</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen6" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(393)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">6,309</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Net cash provided by investing activities</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,351</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">6,309</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Increase (decrease) in cash and cash equivalents and restricted cash</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen10" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">(344)</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">857</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Cash and cash equivalents and restricted cash at the beginning of the period</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">2,130</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">2,998</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Cash and cash equivalents and restricted cash at the end of the period</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen8" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">1,786</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen8" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen8" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">3,855</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Supplemental disclosure of cash flow information:</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Cash received from interest</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">64</span></p>
</td><td class="prngen3" colspan="2" rowspan="1"><p class="prnml4"><span class="prnews_span">$</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">77</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr><tr><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen9" colspan="1" rowspan="1"><br/></td><td class="prngen3" colspan="1" rowspan="1"><br/></td></tr></tbody></table></div><p> </p>
<p> </p>
<p>Logo - <u><a href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg</a></u></p>
<p>SOURCE  Galmed Pharmaceuticals Ltd.</p></div>
